Abstract: A dysmenorrhea relief device includes: a vibrator motor assembly, including a motor configured to vibrate; a power assembly configured to control the motor; and a connector assembly. A first end of the connector assembly couples to the vibrator motor assembly, and a second end couples to the power assembly. The connector assembly includes a connector composed of material that displace 9 mm to 65 mm in a linear stress test of 78 mm±5 mm gage length of the material at 30 N, which allows the connector assembly to be used for inserting and removing the device from a vaginal canal. In the linear stress test, 78 mm±5 mm gage length of the sample resides between grips. A linear pull force is applied to the sample at 2 mm/min. Displacement at different linear pull forces are measured until 30 N of force has been applied.

Abstract: An ultrasonic massage device applying synchronic treatment to multiple parts of human body, including a host, an ultrasonic vibrating motor built in the host, a key panel controlling the ultrasonic vibrating motor, and a plurality of massage heads installed on different sides of the host; the ultrasonic vibrating motor produces and transmits high-frequency ultrasonic vibration to the plurality of massage heads to provide synchronic massage to various body parts. The host with built-in ultrasonic vibrating motor is connected with massage heads at different positions and with different orientations; when the ultrasonic vibrating motor is operating, high-frequency ultrasonic vibration is generated and the massage heads vibrate synchronically. Different parts of human body then receive synchronic massage treatment when in contact with the massage heads.

Abstract: A reinforcing system for a vessel that can contain water is described. The system includes a shell for containing water, the shell having one or more jets extending therethrough from an inside of the shell to an outside of the shell, and a structural support layer on an underside of the shell. The structural support layer can include: an inner layer of rigidizer applied to the underside of the shell, a central low density core, and an outer layer of rigidizer applied to the central low-density core. The structural support layer can extend from a bottom side of the underside of the shell, across at least one sidewall of the underside of the shell, and form at least one rib along the sidewall of the underside of the shell.

Abstract: A human ecological negative oxygen ion cell activation and meridian moxibustion intelligent communication physical therapy platform, including a base plate, lifting assembly and smoke discharging assembly, wherein the lifting assembly is installed at a front surface of the base plate, the smoke discharging assembly is installed inside the base plate and the lifting assembly, and the lifting assembly includes a physical therapy box, sliding rails, threaded rods, a motor, a sliding block and a square block; a C-shaped stander is installed at the front surface of the base plate, two fixing plates are symmetrically installed at an inner surface of the C-shaped stander, at least one installation shielding plate is installed at neighboring sides of the fixing plates, a front surface of the at least one installation shielding plate is installed at outer sides of the sliding rails, the sliding rails are slidably connected with the sliding block.

Abstract: A device for organizing and tracking medication. The device includes compartments to contain medication, and each compartment includes an access door. A sensor element can detect if the device is moved, if the access door is opened and/or closed, and/or if medications have been placed into or removed from a compartment. A processor and/or external computing system provides alarms if medications is not properly taken, a filling service for stuffing the compartments and an administration service to verify the medications are properly taken.

Abstract: An article or vessel is described including a vessel surface and a coating set comprising at least one tie coating, at least one barrier coating, and at least one pH protective coating. For example, the coating set can comprise a tie coating, a barrier coating, a pH protective coating and a second barrier coating; and in the presence of a fluid composition, the fluid contacting surface is the barrier coating or layer. The respective coatings can be applied by PECVD of a polysiloxane precursor. Such vessels can have a coated interior portion containing a fluid with a pH of 4 to 8. The barrier coating prevents oxygen from penetrating into the thermoplastic vessel, and the tie coating and pH protective coating together protect the barrier layer from the contents of the vessel. The second barrier coating is comparable to glass surface if needed.

Abstract: The present invention provides a dental restorative curable composition that has high mechanical strength and toughness and has excellent water resistance and smoothness/gloss durability in the form of a cured product, a dental composite resin comprising the dental restorative curable composition, and a dental mill blank comprising a cured product of the dental restorative curable composition. The present invention relates to a dental restorative curable composition comprising: a (meth)acrylic acid ester compound (A) which has at least one polymer structure selected from the group consisting of a polycarbonate, a polyarylate, and an aromatic polysulfone and in which terminal hydroxy residues derived from repeating units constituting the polymer structure are directly (meth)acryloylated; a (meth)acrylic acid ester compound (B) having two or more (meth)acryloyloxy groups (excluding the (meth)acrylic acid ester compound (A)); an inorganic filler (C) having an average primary particle diameter of 0.

Abstract: An object of the present invention is to provide a dental composition that exhibits small polymerization shrinkage stress, and provides excellent mechanical strength. The present invention relates to a dental composition comprising a compound (A) having a weight-average molecular weight of 2,000 or more, a monomer (B), and a polymerization initiator (C), wherein the compound (A) having a weight-average molecular weight of 2,000 or more has a glass transition region including a temperature range of 20 to 40° C., and the monomer (B) excludes the compound (A) having a weight-average molecular weight of 2,000 or more. The compound (A) having a weight-average molecular weight of 2,000 or more has a weight-average molecular weight of preferably less than 50,000.

Abstract: There is provided a nonwoven fabric for skin care products excellent in adhesion and wiping properties, and soft touch to the skin. The nonwoven fabric includes synthetic fibers and cellulose fibers. When a maximum length of a cross section of the synthetic fibers is denoted by A and a maximum width thereof is denoted by B, flatness expressed by the formula (1) is 1.0 to 1.5: flatness=A/B??(1) the synthetic fibers have recesses, a depth of which is 1.0% or more and 10.0% or less relative to a single fiber diameter of the synthetic fibers, a single fiber diameter of the synthetic fibers is 1 ?m or more and 20 ?m or less, a content of the synthetic fibers is 30 to 70% by mass relative to the entire nonwoven fabric for skin care products, a content of the cellulose fibers is 70 to 30% by mass relative to the entire nonwoven fabric for skin care products, and an average single fiber diameter of all fibers constituting the nonwoven fabric for skin care products is 5 ?m or more and 20 ?m or less.

Abstract: A stick-shaped cosmetic material including two or more regions divided in a longitudinal direction of the stick-shaped cosmetic material, in which the two or more regions include a first region containing a first cosmetic composition containing a wax (A1) having a melting point of 65° C. or higher as an oil component in the first cosmetic composition, and a second region containing a second cosmetic composition containing, as oil components in the second cosmetic composition, the wax (A1) and a fatty acid triglyceride (A2) having a melting point of 30° C. or higher, the first region and the second region are adjacent to each other, and when content ratios (mass %) of the wax (A1) based on a total amount of the oil components in the first cosmetic composition and the second cosmetic composition are defined as M1 and M2, respectively, M1>M2 is satisfied.

Abstract: Disclosed herein are novel cosmetics or sunscreen preparations to absorb or scatter ultraviolet light and simultaneously scavenge free radicals, holes, electrons, or reactive oxygen species, and methods of preparing the same.

Abstract: Matrix particles containing one or more matrix materials and one or more hydrophobic active agents, agglomerated particles made therefrom, fibrous structures containing such matrix particles and/or agglomerated particles, and processes for making same are provided.

Abstract: The present invention provides a water-in-oil emulsified cosmetic composition comprising a hydrophobized pigment (A), a silicon film former (B), a silicone-based surfactant having an HLB value of 2 to 8 (C), and optionally a non-volatile oil (D), wherein component (A) is at least one kind of an inorganic pigment except for calcium phosphate, which is treated with a hydrophobizing agent except for a bisbenzoyl compound, the ratio of the mass of component (B) to the total mass of component (C) and component (D) is 1.0 to 9.0, and no fluoroether compound is contained in the composition.

Abstract: Various aspects disclosed relate to provides a mascara composition. The mascara composition includes a water-in-silicone emulsion. The emulsion includes an emulsifier, a continuous phase, and a discontinuous phase. The continuous phase includes a silicone component and a wax component. The discontinuous phase includes water and a preservative component.

Abstract: The present invention relates to a composition for lightening keratin fibres, comprising at least one chemical oxidizing agent, ammonium carbonate and at least one silicate, and also to a process for lightening keratin fibres using this composition.

Abstract: The invention relates to calcium hydroxyapatite particles having been sintered at a certain temperature range and which are not treated at a temperature above this range. Furthermore, the present invention relates to an injectable composition comprising such particles and to uses thereof. Surprisingly, it was found that the particles of the invention are superior over calcium hydroxyapatite particles known in the art with respect to bio-stimulation.

Abstract: This invention relates to oral care compositions comprising zinc phosphate, a first source of stannous (e.g., stannous fluoride); and a second source of stannous, wherein the second source of stannous comprises stannous pyrophosphate, as well as to methods of using and of making these compositions.

Abstract: Cosmetic compositions, kits thereof, and methods of making and using such cosmetic compositions. The cosmetic compositions typically include about 20 to about 95 wt. % of a polyol; about 5 to about 70 wt. % of one or more monoalcohols having from 2 to 6 carbon atoms; about 0.1 to about 10 wt. % of one or more cationic surfactants; about 0.1 to about 20 wt. % of one or more fatty compounds; and about 1 to about 15 wt. % of a combination of a urea compound and citric acid, wherein all weight percentages are based on the total weight of the cosmetic composition. The cosmetic compositions have a weight ratio of polyol to monoalcohol(s) that is from 20:1 to 1:20. Additionally, the cosmetic compositions typically have a mole ratio of citric acid to urea compound of that is about 10:0.5 to about 0.5:10.

Abstract: Various compositions and methods for treating or preventing damage to hair, especially in over-processed or chemically treated hair, are described. The various compositions comprise itaconic acid, or a salt, ester, or anhydride thereof, and are applied in the absence of any oxidizing agent.

Abstract: A compound that includes a menthol glycinate. The menthol glycinate includes a menthol connected to a glycine or glycine derivative, via an ester linkage. The groups on the N atom are referred to as R1 and R2, and R1 and R2 are independently selected from the group consisting of: alkyl and R1 and R2 together with the N atom to which they are attached form a 4-8-member ring. R1 and R2 each contain at most 20 carbon atoms.

Abstract: A water-in-oil type composition, including (A) an organic modified clay mineral, (B) 3% by mass or greater of a polar oil having IOB of 0.3 or higher, (C) a nonpolar oil having an alkyl side chain, (D1) a polyoxyethylene hardened castor oil, and (D2) an emulsification activating agent, that is a compound having an alkyl side chain containing 10 or more carbon atoms, or a compound having a fatty acid side chain containing 10 or more carbon atoms or a polyoxyethylene adduct of the compound.

Abstract: A subject of the present invention is a cosmetic composition comprising 6-hydroxybenzornorpholine of formula (II), hydroxyethyl-3,4-methylenedioxyaniline of formula (III), at least one compound chosen from N,N-dicarboxymethylglutamic acid, its salts and mixtures thereof. The present invention also relates to a process for dyeing keratin fibres, such as the hair, wherein the composition as described previously is applied to said fibres. Another subject of the present invention is the use of the composition according to the invention for the cosmetic treatment of keratin fibres such as the hair.

Abstract: The invention relates to extremely mild, concentrated cleansing compositions to create personal care formulations. The mildness of composition towards the skin is due to the synergy of constituent members. More specifically, the compositions comprise of cocamidopropyl PG dimonium chloride phosphate, an alkyl polyglucoside, and sophorolipids to give the superlative performance in terms of foam and lather with extreme gentleness towards the stratum corneum, the uppermost layer of the skin. The concentrated, self-preserving, ultra-mild compositions of the present invention are particularly suitable for cleansing of sensitive skin (babies and sensitive body parts), irritated skin (medically compromised) and very dry skin (senior citizens). Also process for preparing such ultra-mild cleansing composition is provided.

Abstract: A dry formulation useful to prepare a hair care product is provided. The formulation comprises: i) a water soluble film-forming polymer; ii) at least one hair product ingredient, and iii) optionally, a pH adjuster in an amount sufficient to establish a pH in the range of about 3.0 to about 7.5. The dry formulation may be further processed, for example, prepared into tablets or other dosage forms, for ease of use. Methods of making the hair care product are also provided, as well as kits containing the formulation.

Abstract: The present invention is to provide a solid lip cosmetic which is excellent in secondary adhesion resistance effect and long lasting performance and has a good feeling of adhesion. A solid lip cosmetic with secondary adhesion resistance effect and has a good feeling of adhesion can be prepared by blending a copolymer containing a dimer acid ester, and/or a dimer acid ester as an oil component adhering to lips (adhesive oil component), and a phenyl-modified silicone as an oil component seeping into the surface upon application to the lips (seeping oil component).

Abstract: Nutraceutical formulations, which could be used for wholistic skin care and treatment purposes, with enhanced organoleptic properties have elements of biological origin more particularly a herbal formulation(s).

Abstract: The present disclosure relates to an ultraviolet light-blocking composition containing a centipede grass extract and a cosmetic composition and, more specifically, to an ultraviolet light-blocking composition comprising a centipede grass (Eremochloa ophiuroides) leaf extract as an active ingredient; and a cosmetic composition containing the ultraviolet light-blocking composition.

Abstract: A method for obtaining a culture supernatant form microalgae is provided, particularly wherein the culture supernatant is IMAC-enriched microalga culture supernatant and to an IMAC-enriched microalga culture supernatant obtained by the method of the invention. Also provided is a combination having a microalgal culture supernatant and a growth factor and to a cell culture media; a cosmetic composition and pharmaceutical composition and uses thereof.

Abstract: A method for the treatment of an auditory disease or condition in a human subject is provided comprising administering a therapeutic agent into a bony cavity of a cochlea of the subject that contains neural structures via the Round Window membrane of the cochlea. Also provided are therapeutic agents for use in such methods, as well as method for the delivery of therapeutic agents via the Round Window membrane of the cochlea.

Abstract: Provided is an oral pharmaceutical composition characterized by containing a medicinal ingredient (A), a hydrophobic liquid (B), a water-soluble macromolecular substance (C), and an excipient (D), but not containing a surfactant, wherein: the medicinal ingredient (A) is included in the hydrophobic liquid (B); and the hydrophobic liquid (B) is dispersed in a composition including the water-soluble macromolecular substance (C) and the excipient (D). The oral pharmaceutical composition: allows easy dose-adjustment; has excellent dosability and safety; is biologically equivalent to a standard formulation having established profiles regarding efficacy, safety, etc.; and can be easily produced.

Abstract: The present invention relates to a method for producing a multi-layer oral thin film comprising the steps of a) providing a solution, an emulsion, a foam or a suspension comprising at least one first polymer, b) processing the solution, the emulsion, the foam or the suspension from step a) in order to obtain a polymer film, c) applying a powder comprising at least one second substance, which preferably differs from the first polymer, to the polymer film, and d) forming a composite between the polymer film and the powder applied in step c), to a multi-layer oral thin film obtainable by this method, and to the use of a multi-layer oral thin film obtainable by this method as a medicament.

Abstract: The present disclosure relates to electrospun patches comprising therapeutic polypeptides. The patches include an impermeable layer that functions as a barrier, e.g., to prevent to penetration of water. Upon attachment of the patch to skin or mucosa, the therapeutic polypeptide is released in order to treat a variety of diseases and conditions.

Abstract: A pharmaceutical composition of ivermectin nano-suspension is provided, which is suitable for nebulizer, where dispersion medium is water, containing at least 0.1 mg/mL tween 80 stabilizer.

Abstract: The invention relates to an artificial vitreous humor composition comprising a phosphate buffer, wherein the phosphate buffer has a pH value in the range from 7.0 to 7.7, particularly from 7.1 to 7.6, more particularly from 7.2 to 7.5. The invention further relates to a method of production of an artificial vitreous humor composition, a method for analyzing the behavior of a substance, a method for analyzing the change of the artificial vitreous humor composition upon contact with a substance and a kit of parts.

Abstract: The present invention provides a pharmaceutical composition for application to the skin comprising epinastine or a salt thereof in a concentration of 0.05 to 1% (w/w) as an active ingredient which can maintain the concentration of the active ingredient for a long time even at lower concentrations.

Abstract: The invention relates to the treatment of cancer. In one embodiment, the present invention provides a composition comprising a micelle construct attached to a curcumin molecule or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent. In another embodiment, the present invention provides a method of treating cancer by administering a therapeutically effective amount of a composition comprising a micelle construct attached to curcumin or a pharmaceutical equivalent, analog, derivative, or salt thereof, and a chemotherapy agent.

Abstract: Nanovesicles derived from plants of biological origin, comprising a lipid membrane and within the lipid membrane at least one bioavailable antioxidant substance, and use of the same nanovesicles for nutraceutical, cosmetic and regenerative use.

Abstract: Cryogranulation systems with improved dispenser assemblies are provided for use in manufacturing frozen pellets of pharmaceutical substances in a fluid medium. Methods of cryogranulating the pharmaceutical substance in the fluid medium are also provided. In particular embodiments, the dispenser assembly is used with suspensions or slurries of pharmaceutical compositions including biodegradable substances, such as proteins, peptides, and nucleic acids. In certain embodiments, the pharmaceutical substance can be adsorbed to any pharmaceutically acceptable carrier particles suitable for making pharmaceutical powders. In one embodiment, the pharmaceutical carrier can be, for example, diketopiperazine-based microparticles. The dispenser assembly improves the physical characteristics of the cryopellets formed and minimizes product loss during processing.

Abstract: Lyophilized formulations of tegavivint, methods of making such formulations, and methods of treatment of cancer by administering the formulations.

Abstract: The present disclosure provides tablet formulations including a triphenyl calcilytic compound for the treatment of autosomal dominant hypocalcemia (ADH), where the compound is represented by formula (I): a solvate, a hydrate, a pharmaceutically acceptable salt, or a combination thereof.

Abstract: A method for fabricating a medical braided capsule may include braiding a multi-layer shell onto a powder injection pipe by moving the powder injection pipe linearly up and down in a braiding zone of a braiding machine, discharging a powder from the powder injection pipe into the multi-layer shell, and moving the powder injection pipe out of the multi-layer shell. Discharging the powder from the powder injection pipe into the multi-layer shell and moving the powder injection pipe out of the multi-layer shell are carried out simultaneously.

Abstract: Described herein is a composition for oral delivery of mammalian exosomes, the composition comprising a plurality of mammalian exosomes admixed with a matrix and surrounded by an enteric coating, the matrix comprising a matrix comprising about 0.5% to about 3.0% methyl cellulose and about 0.5% to about 3.0% alginate gel. Also described herein is a composition for rectal or vaginal delivery of mammalian exosomes, the composition comprising a lipophilic or hydrophilic coating surrounding a plurality of mammalian exosomes admixed with a matrix in solid form, the matrix comprising a matrix comprising about 0.5% to about 3.0% methyl cellulose and about 0.5% to about 3.0% alginate gel.

Abstract: The invention relates to nucleic acid nanostructure delivery compositions for non-viral delivery, and methods therefor. More particularly, the invention relates to nucleic acid nanostructure delivery compositions, such as DNA origami compositions, for the delivery, for example, of small molecule therapeutics, and methods therefor.

Abstract: The invention describes particles having a polypeptide shell. The polypeptide shell comprises at least one immunomodulatory polypeptide. Particles may be ultrasound-responsive particles, providing the ability to administer particles trandermally, or deliver particles to selected sites by use of ultrasound. Administration of the particles generates immunologic response to the polypeptide in the shell of the particle. The particles are therefore useful in methods of immunotherapy.

Abstract: The present invention relates generally to pharmaceutical formulations. Particularly, the present invention relates to a new delivery system for delivery of medical components to the lungs, and its utility in the fields of pharmaceutical formulation, drug delivery, medicine and diagnosis.

Abstract: The present invention relates to a method of forming polymeric microparticles housing live microorganisms, the method using the steps of (a) providing a microbial solution comprising a crosslinkable polymeric material compatible with live microorganisms; a protective agent; a microbial population; and water; and a crosslinking agent solution comprising a crosslinking agent and water; and (b) subjecting the microbial and crosslinking agent solutions to spray-drying using a co-axial nozzle configured to spray at least three fluids independently, thereby producing microparticles of a crosslinked polymeric material housing live microorganisms where the microbial solution and crosslinking agent solution are each sprayed through one of the innermost two channels of the co-axial nozzle and an atomizing gas is sprayed through the outermost channel. In a specific embodiment, the polymeric material is alginate, and the microbial population is selected from one or more of probiotic bacteria and/or a live biotherapeutic.

Abstract: Novel process and products thereby emplace NSAIDS within nanodelivery vehicles for various indications in mammals, including humans.

Abstract: Methods of delivering a transgene to a subject in need thereof are described. In particular, the methods include administering to the subject (i) a phagocyte-depleting agent, and (ii) a pharmaceutical composition comprising a non-viral vector comprising the transgene and a pharmaceutically acceptable carrier. The methods can be used to treat a subject in need of treatment for a disease caused by a loss of function or activity of a protein, or to treat a subject in need of treatment for a disease caused by a gain of function activity or expression of a protein.

Abstract: Methods, systems, and devices are disclosed for encapsulating biological entities with preservation of their biological activity. In one aspect, a method of encapsulating a biological entity includes templating a biocompatible material onto a biological structure to form a coating structure enclosing the biological structure, the coating structure having a size in the nanometer range, in which the coated biological structure preserves its biological activity within the coating structure. In some implementations of the method, the biological structure includes a virus and the biocompatible material includes silica.

Abstract: Monolithic-style dermal patches and reservoir-style dermal patches are provided. The dermal patches are capable of delivering to a patient, consumer, user, or human subject, one or both of psilocybin and psilocin, preferably with one or more cannabinoids, such as cannabidiol (CBD).